GlassScriptPhysician profile
Timothy Mark Biagini
NPI 1568618544
$3,562.08
in general payments reported to CMS, 2019-2025
16 companies · $1,189 in 2025
The $1,189 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $514 · 2020: $275 · 2021: $261 · 2022: $186 · 2023: $447 · 2024: $689 · 2025: $1,189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,249 · Education: $76.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,249.39 |
| Education | $76.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,023.08 | 2019-2025 | Skyrizi, Viberzi, Linzess |
| Janssen Biotech, INC. | $732.81 | 2020-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $677.77 | 2019-2025 | Entyvio, Eohilia |
| Allergan, INC. | $400.00 | 2019 | |
| Gilead Sciences, INC. | $179.43 | 2020-2025 | |
| Conmed Corporation | $124.42 | 2024 | Conmed Hemostasis |
| Intercept Pharmaceuticals, INC. | $91.71 | 2021-2025 | Ocaliva |
| Aimmune Therapeutics, INC. | $90.58 | 2025 | Zenpep |
| Janssen Pharmaceuticals, INC | $45.40 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.79 | 2020-2023 | Xifaxan |
| Boston Scientific Corporation | $35.85 | 2020-2021 | |
| Olympus America INC. | $26.83 | 2025 | Disposable Biopsy Forceps, Endoclot Phs, Single Use Repositionable Clip |
| Pfizer INC. | $25.57 | 2020-2021 | |
| Ucb, INC. | $25.54 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $24.38 | 2025 | Iqirvo |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $14.92 | 2023 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Biagini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.